1. Home
  2. |Insights
  3. |Court Tackles Hubzone Issues In Two Cases

Court Tackles Hubzone Issues In Two Cases

Client Alert | less than 1 min read | 04.12.05

In Mark Dunning Industries, Inc. v. U.S. (Mar. 4, 2005), the Court of Federal Claims, after finding it has jurisdiction to review a SBA protest decision of a bidder's HUBZone qualification, decided that the SBA had appropriately found the bidder qualified because its "principal office" (which was in a HUBZone) was different from its headquarters (which was not). In Manson Construction Co. v. U.S. (Mar. 14, 2005), the court validated award to the second-low bidder which won because of application of the HUBZone preference, while also upholding the agency's revision of its internal estimate that brought the contractor within the "zone" of permissible cost.

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights